Castrate Resistant Prostate Cancer (CRPC) Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Castrate Resistant Prostate Cancer (CRPC) Epidemiology Forecast Report Coverage

Expert Market Research's “Castrate Resistant Prostate Cancer (CRPC) Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of castrate resistant prostate cancer. It projects the future incidence and prevalence rates of castrate resistant prostate cancer cases across various populations. The study covers age, gender, and type as major determinants of the castrate resistant prostate cancer (CRPC) population. The report highlights patterns in the prevalence of castrate resistant prostate Cancer (CRPC) over time and projects future trends based on multiple variables.

Castrate Resistant Prostate Cancer (CRPC) Understanding: Disease Overview

CRPC is a stage of prostate cancer where disease progresses despite androgen deprivation therapy, including surgical or chemical castration. Patients may present with rising prostate-specific antigen (PSA) levels, worsening symptoms, or new metastases. It can be classified as metastatic or non-metastatic, and symptomatic burden varies. CRPC predominantly affects older men, often leading to bone, lymph node, or visceral metastases, significantly impacting quality of life. Early identification and monitoring are crucial for timely intervention and improved survival outcomes.

Castrate Resistant Prostate Cancer (CRPC) Epidemiology Perspective

The castrate resistant prostate cancer (CRPC) epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the castrate resistant prostate cancer (CRPC) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for castrate resistant prostate Cancer (CRPC) and their trends. The castrate resistant prostate cancer (CRPC) detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Prostate cancer is a leading male malignancy worldwide, with about 1.4 million new cases and 375,000 deaths in 2020; CRPC arises as a progression in many advanced patients.
• The majority of CRPC cases occur in those >65 years of age, consistent with prostate cancer demographics. In countries with large aging populations (e.g., Europe, North America), a higher absolute burden of CRPC exists due to the larger elderly male population.
• In a UK primary-care database, about 28% of castrate prostate cancer patients developed CRPC over the study period, equating to an incidence of ~8.3 per 100 person-years among castrate PCa patients.
• Global prostate cancer incidence is highest in regions like Northern America and Australia/New Zealand with age‑standardized rates near 97.2 and 111.6 per 100,000 males, respectively; CRPC follows this pattern as the disease advances.

Read more about this report - Request a Free Sample

Country-wise Castrate Resistant Prostate Cancer (CRPC) Epidemiology Segment

The castrate resistant prostate cancer (CRPC) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

In the United States, castrate-resistant prostate cancer (CRPC) represents a critical stage of prostate malignancy, with about 1.1% of prostate cancer patients identified as metastatic CRPC in a managed-care population. Prevalence has increased over time, reflecting longer survival with modern therapies. Median survival for metastatic CRPC patients is approximately 3 years, while the overall five-year survival rate for metastatic prostate cancer is around 38%, encompassing both hormone-sensitive and resistant cases. These data underscore the ongoing clinical burden of advanced prostate cancer and the importance of effective management strategies.

Castrate Resistant Prostate Cancer (CRPC): Treatment Overview

Management of CRPC involves a combination of hormonal therapies, chemotherapy, immunotherapy, and radiopharmaceuticals. Androgen receptor inhibitors like enzalutamide or apalutamide are used for non-metastatic disease, while docetaxel or cabazitaxel chemotherapy is indicated for advanced or metastatic cases. Bone-targeted therapies, such as radium-223, reduce skeletal complications. Treatment choice depends on metastatic status, patient comorbidities, prior therapy, and symptom burden, with multidisciplinary care improving survival and quality of life. Clinical trials explore novel combination therapies to delay progression further.

Key Questions Answered

• What are the key findings of castrate resistant prostate cancer (CRPC) epidemiology in the 8 major markets?
• What will be the total number of patients with castrate resistant prostate cancer (CRPC) across the 8 major markets during the forecast period?
• What was the country-wise castrate resistant prostate cancer (CRPC) epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of castrate resistant prostate cancer (CRPC) during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of castrate resistant prostate cancer (CRPC) during the forecast period of 2026-2035?
• What are the currently available treatments for castrate resistant prostate cancer (CRPC)?
• What are the disease risks, signs, symptoms, and unmet needs of castrate resistant prostate cancer (CRPC)?

Scope of the Castrate Resistant Prostate Cancer (CRPC) Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of castrate resistant prostate cancer (CRPC) based on several factors.
• Castrate Resistant Prostate Cancer (CRPC) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The castrate resistant prostate cancer (CRPC) report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Prostate Cancer Market

Castrate-Resistant Prostate Cancer Market